I need to make a small correction to my previous post. The four studies totaled ~900 patients...not 1200. (Still considered to be very significant, IMO)
Again, you should pay close attention to the end of the video starting at the 18-minute and especially the 21-minute mark. THIS is why I believe there was so much insider buying.
The combined data from all four studies (which is around 900 patients) compared to the SOC (as shown on the chart) is very impressive.
https://www.annovisbio.com/video-library
Again, you should pay close attention to the end of the video starting at the 18-minute and especially the 21-minute mark. THIS is why I believe there was so much insider buying.
The combined data from all four studies (which is around 900 patients) compared to the SOC (as shown on the chart) is very impressive.
https://www.annovisbio.com/video-library
Recent ANVS News
- Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026 • GlobeNewswire Inc. • 05/07/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 09:02:41 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:55:10 PM
- Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio • GlobeNewswire Inc. • 04/28/2026 12:00:00 PM
- Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission • GlobeNewswire Inc. • 04/10/2026 12:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/09/2026 09:09:42 PM
- Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants • GlobeNewswire Inc. • 04/09/2026 12:30:00 PM
- The Credibility Filter Wall Street Uses to Sort Biotech Winners • GlobeNewswire Inc. • 04/08/2026 01:15:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2026 08:39:11 PM
- Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections • GlobeNewswire Inc. • 04/02/2026 11:30:00 AM
- Annovis Publishes Historical Review of Buntanetap in The Scientist • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 09:19:03 PM
- NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 09:06:04 PM
- Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results • GlobeNewswire Inc. • 03/16/2026 11:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/13/2026 09:15:44 PM
- Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference • GlobeNewswire Inc. • 03/03/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 02:00:47 PM
- Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease • GlobeNewswire Inc. • 02/12/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/28/2026 09:28:34 PM
- Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients • GlobeNewswire Inc. • 12/18/2025 09:35:00 PM
- Annovis to Host Corporate Update Webinar on January 28, 2026 • GlobeNewswire Inc. • 12/16/2025 01:00:00 PM
- Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group • GlobeNewswire Inc. • 12/03/2025 01:00:00 PM
- Annovis Announces Two Presentations at the CTAD 2025 Conference • GlobeNewswire Inc. • 11/24/2025 01:00:00 PM
